
Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

Drs Nicola Hanania and Francesca Polverino explore the Many Faces of COPD: From Phenotypes to Endotypes.
An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.

In this video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the current and emerging treatment options for children with AD uncontrolled with topical therapy, including a summary of recent long-term data for advanced systemic therapies

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.

Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.

Highlights from the ADVENT educational symposium at EADV 2024 where Professors Eric Simpson, Stephan Weidinger, and Marjolein de Bruin-Weller explored the local and systemic effects of type 2 inflammation in AD and potential benefits of early intervention with regard to disease modification.